Cancer Vaccine

Cancer vaccines have moved from an experimental concept to one of oncology's most promising fields. As of July 2026, personalized mRNA vaccines, neoantigen vaccines, dendritic cell vaccines, and viral-vector platforms are demonstrating encouraging clinical results, particularly in melanoma and pancreatic cancer. While no personalized mRNA cancer vaccine has yet received full regulatory approval, several late-stage clinical trials suggest that the first approvals could occur within the next few years.